The Food and Drug Administration has granted expanded access for treatments employing the drug commonly known as "ecstasy," or MDMA.

H/T: Breitbart

In a Friday press release, the Multidisciplinary Association for Psychedelic Studies (MAPS) announced that “the U.S. Food and Drug Administration (FDA) has agreed to MAPS’ application for an Expanded Access program for MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD).”

“We commend FDA for recognizing the great unmet medical need of PTSD by allowing access to MDMA-assisted psychotherapy on a compassionate basis for people with treatment-resistant PTSD,” said MAPS Founder and Executive Director Rick Doblin, Ph.D. “We are delighted to begin generating real-world evidence about this potential new treatment.”

An international study found that MDMA has serious promise for treating PTSD 💊 💊 💊 https://t.co/5kplouZxsB — MERRY JANE (@MERRYJANE) January 25, 2020

PRESS RELEASE: FDA Agrees to Expanded Access Program for MDMA-Assisted Psychotherapy for PTSD - MAPS https://t.co/aQIbuDh3d3 — Stella Vote Blue (@QuirkyGirl9) January 25, 2020

“We’re looking at possible FDA approval for treatment at the end of 2021, and the accessibility of treatment in clinics by 2022,” said Brad Burge, a spokesperson for MAPS. https://t.co/laDn3I3GZv — FOX 32 News (@fox32news) January 24, 2020